[{"address1": "1167 Massachusetts Avenue", "city": "Arlington", "state": "MA", "zip": "02476", "country": "United States", "phone": "781 996 5252", "fax": "781 642 0399", "website": "https://www.kalarx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark T. Iwicki", "age": 57, "title": "Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1013436, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd  Bazemore", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 733580, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. R. Kim Brazzell Ph.D.", "age": 70, "title": "Head of R&D and Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 709485, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  Hanes Ph.D.", "title": "Founder & Chair of the Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary  Reumuth CPA", "age": 48, "title": "CFO & Treasurer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jill S. Steier", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent  Kosewski", "age": 60, "title": "Senior VP of Manufacturing & Supply Chain Management", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darius  Kharabi J.D., M.B.A.", "age": 43, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Francis S. Mah M.D.", "title": "Chief Medical Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Josiah  Craver", "title": "Senior VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.82, "open": 6.78, "dayLow": 6.7157, "dayHigh": 7.1699, "regularMarketPreviousClose": 6.82, "regularMarketOpen": 6.78, "regularMarketDayLow": 6.7157, "regularMarketDayHigh": 7.1699, "beta": -2.041, "forwardPE": -0.9114927, "volume": 75031, "regularMarketVolume": 75031, "averageVolume": 237255, "averageVolume10days": 1350450, "averageDailyVolume10Day": 1350450, "bid": 6.8, "ask": 6.99, "bidSize": 100, "askSize": 100, "marketCap": 30766480, "fiftyTwoWeekLow": 4.21, "fiftyTwoWeekHigh": 15.94, "fiftyDayAverage": 6.41466, "twoHundredDayAverage": 7.154675, "currency": "USD", "enterpriseValue": 7517532, "floatShares": 1711108, "sharesOutstanding": 4458910, "sharesShort": 13520, "sharesShortPriorMonth": 6029, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 0.08604, "heldPercentInstitutions": 0.47924, "shortRatio": 0.47, "shortPercentOfFloat": 0.0052, "impliedSharesOutstanding": 4458910, "bookValue": 2.365, "priceToBook": 2.9175477, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -39551000, "trailingEps": -14.56, "forwardEps": -7.57, "pegRatio": -0.01, "lastSplitFactor": "1:50", "lastSplitDate": 1666310400, "enterpriseToEbitda": -0.185, "52WeekChange": -0.53061223, "SandP52WeekChange": 0.26253593, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KALA", "underlyingSymbol": "KALA", "shortName": "KALA BIO, Inc.", "longName": "KALA BIO, Inc.", "firstTradeDateEpochUtc": 1500557400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "06a09f76-df06-3807-bce5-79032313c0fe", "messageBoardId": "finmb_83652421", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.9, "targetHighPrice": 22.0, "targetLowPrice": 15.0, "targetMeanPrice": 18.33, "targetMedianPrice": 18.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 48478000, "totalCashPerShare": 17.212, "ebitda": -40568000, "totalDebt": 36562000, "quickRatio": 4.081, "currentRatio": 4.216, "debtToEquity": 548.897, "returnOnAssets": -0.40776002, "returnOnEquity": -2.62605, "freeCashflow": -18252376, "operatingCashflow": -29087000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]